Intra-Cellular Therapies, Inc.
ITCI
Peringkat dalam Saham
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Harga Saham
$131.87
Terakhir disinkronkan: 2025-04-02
Kapitalisasi Pasar
$12.68B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Jumlah saham beredar untuk Intra-Cellular Therapies, Inc. (ITCI)
Jumlah saham beredar per December 2024: 103.13M
Menurut laporan keuangan terbaru dan harga saham Intra-Cellular Therapies, Inc., jumlah saham beredar saat ini adalah 103.13M. Pada akhir December 2023, perusahaan memiliki 95.88M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Intra-Cellular Therapies, Inc. (ITCI) dari 2013 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 103.13M | 0.00% |
| 2024 | 103.13M | 7.56% |
| 2023 | 95.88M | 1.95% |
| 2022 | 94.05M | 15.74% |
| 2021 | 81.25M | 15.47% |
| 2020 | 70.36M | 27.50% |
| 2019 | 55.19M | 0.87% |
| 2018 | 54.71M | 18.46% |
| 2017 | 46.18M | 6.80% |
| 2016 | 43.24M | 20.07% |
| 2015 | 36.01M | 25.69% |
| 2014 | 28.65M | 66.35% |
| 2013 | 17.22M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 2,226.49% |
IN
|
